Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.
The objective of this study was: (1) to characterize the P-gp inhibitory effect of different concentrations of Pluronic P85 on anti-HIV-1 drug cellular accumulation, and (2) to investigate the relationship between cellular accumulation and free fraction of drug. Cellular accumulation studies in MDCKII-WT and MDCKII-MDR1 cell monolayers showed a biphasic dose response characterized by decline in accumulation at Pluronic concentrations greater than the CMC. This phenomenon was independent of the inhibition of P-gp efflux by Pluronic. Cell-free equilibrium dialysis was used to determine the effect of Pluronic P85 on drug free fraction and the affinity of Pluronic micelles for drug was modeled. Nelfinavir and saquinavir associated extensively with micelles and equilibrium free fractions were low at P85 concentrations above the CMC, with association constants being in the order nelfinavir > saquinavir >>> abacavir. Abacavir, a P-gp substrate, showed no association with micelles yet showed a biphasic response in cellular accumulation. These data suggest that, above the CMC, inhibition of P-gp is not affected but rather factors such as micellar trapping could contribute to decreased accumulation. Therefore, the in vitro evaluation of the effect of Pluronic formulations on active transport should take into account both the physicochemical properties of drug and the composition of Pluronic.
Shaik
Naveed
N
Department of Pharmaceutics, College of Pharmacy, University of Minnesota, 308 Harvard St. SE, Minneapolis, Minnesota 55455, USA.
Giri
Nagdeep
N
Elmquist
William F
WF
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000166:Acridines / Q000494:pharmacology; D000818:Animals; D001693:Biological Transport, Active / Q000187:drug effects; D002460:Cell Line; D002474:Cell-Free System; D002477:Cells / Q000378:metabolism*; D003956:Dialysis; D015224:Dideoxynucleosides / Q000378:metabolism; D004161:Diphenylhexatriene / Q000378:metabolism; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D018432:Drug Resistance, Multiple / Q000187:drug effects; D005456:Fluorescent Dyes / Q000378:metabolism; D015497:HIV-1 / Q000201:enzymology; D020128:Inhibitory Concentration 50; D008353:Mannitol / Q000276:immunology; D008823:Micelles; D019888:Nelfinavir / Q000378:metabolism; D010539:Permeability; D020442:Poloxamer / Q000494:pharmacology*; D011480:Protease Inhibitors / Q000494:pharmacology; D019258:Saquinavir / Q000378:metabolism; D013501:Surface-Active Agents / Q000494:pharmacology*; D013696:Temperature; D044005:Tetrahydroisoquinolines / Q000494:pharmacology; D013997:Time Factors; D000099227:Abacavir
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000166:Acridines; D015224:Dideoxynucleosides; D004161:Diphenylhexatriene; D005456:Fluorescent Dyes; D008353:Mannitol; D008823:Micelles; D019888:Nelfinavir; D020442:Poloxamer; D011480:Protease Inhibitors; D019258:Saquinavir; D013501:Surface-Active Agents; D044005:Tetrahydroisoquinolines; D000099227:Abacavir; C083501:Elacridar